The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Primary endpoint results of the CLL12 trial
The primary endpoint results of the CLL12 trial (NCT02863718) were presented at the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. We discussed the trial, which investigated ibrutinib vs. a placebo in asymptomatic, untreated chronic lymphocytic leukemia (CLL) patients, with Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, here at the meeting.
